1. Introduction {#sec1}
===============

Synthetic biology has expanded our ability to engineer bio-based routes for the production of added-value chemicals, through rational genetic design and metabolic engineering ([@bib20]; [@bib48]; [@bib60]; [@bib72]). Progress in synthetic biology automation is leading to the establishment of biofoundry and biorefinery pipelines where the design, selection, robotic assembly and testing of engineered microbial strains is increasingly performed in an automated manner ([@bib4]; [@bib14]; [@bib18]; [@bib30]). The current capabilities of biomanufacturing foundries have been demonstrated for several classes of compounds ([@bib16]), including the application of a rapid *Design-Build-Test-Learn* (DBTL) pipeline for iterative optimization of production strains ([@bib14]), and machine learning for the translational tuning of biosynthetic pathways ([@bib33]). Despite such successes in producing natural added-value chemicals, few bio-based alternatives to established chemical products have reached the market, and much effort has to be dedicated toward increasing bioproduction yield ([@bib22]; [@bib24]; [@bib69]). The challenge is particularly compelling for compounds, including bio-based material building blocks, which are prevalent in modern daily life but are mainly derived from petrochemicals, with associated environmental and sustainability concerns. Bio-based production using synthetic biology could provide alternative green routes from renewable resources, allowing cleaner production processes by removing the need for harsh solvents and chemicals and by reducing associated waste ([@bib1]; [@bib3]; [@bib37]; [@bib41]; [@bib73]). Further potential benefits from synthetic biology production approaches include rapid access to chemical diversity and the exploitation of enzymatic specificity, which can tackle chemistry that is difficult or not possible through organic synthesis, such as chiral specificity, regioselectivity or functionalization for improved properties ([@bib66]).

In this study, we applied a semi-automated synthetic biology pipeline to construct microbial strains capable of producing a range of materials monomers via fermentation of simple carbon sources. Our goal was to benchmark and demonstrate the capabilities of the DBTL approach to provide on-demand biosynthetic routes to chemical building blocks for materials ([Fig. S1A](#appsec1){ref-type="sec"}). An important goal was to provide a competitive, widely applicable workflow, which is compound agnostic and can be applied to multiple targets in parallel with a short time to delivery, a requirement seldom achieved in synthetic chemistry production processes. The assessment presented here provides precise metrics on the ability of biomanufacturing foundries to rapidly deliver diverse bio-based monomers for sustainable materials applications. To that end, we applied a synthetic biology pipeline comprising state-of-the-art bioproduction pathway design tools, robotized strain engineering, and high-throughput product quantification. The pipeline proceeds iteratively through sequential steps, starting with the identification of a target compound of interest. Retrosynthetic *design* algorithms are used to explore known and putative biochemical routes connecting the target chemical to the metabolism of the host organism. DNA sequences encoding enzymes to catalyze each reaction in the pathway are then designed, synthesized and screened for activity. The build and test steps of the pipeline proceed through an automated platform for genetic pathway assembly, bacterial chassis construction and culture, followed by automated high-throughput screening and quantification of key metabolites and target compounds.

The materials biomanufacturing pipeline was benchmarked based on multiple metrics, including target titers and time to delivery, using *Escherichia coli* as a production strain. The purpose of selecting *E. coli* was to perform rapid prototyping of the bio-based synthetic routes in a well-characterized host, which could later be transferred to other industrial strains for further optimization. We demonstrate how, for several of our targets, the application of our synthetic biology pipeline led to prototype production strains with target titers comparable to those reported for optimized *E. coli* shake-flask cultures ([Table 1](#tbl1){ref-type="table"}). Over 85 days we were able to produce 17 potential materials monomers and key intermediates *in vivo*. To explore the scale-up potential of our microbial production strains, we dedicated a second 65-day period to optimizing the production of mandelic acid and hydroxymandelic acid at high enantiopurity. We succeeded in producing 0.8--4.8 g/L of the (*R*)- and (*S*)-enantiomers of both targets from glucose or glycerol in fed-batch fermenter cultures. This study provides a *proof-of-concept* for the promising capabilities of synthetic biology pipelines for the production of materials monomers, and showcases how prototype producer strains can be optimized towards industrially relevant titers and economy-efficient production processes.Table 1**Summary of material monomer targets ordered by compound class.** Targets are given by their common name, CAS number and three-letter code used in this study. Days to production: days from target selection to first *in vivo* production. Titers are listed as mean values (±standard deviation) for *E. coli* production strains grown at 30 °C for 24 h in TBP media supplemented with 0.4% glycerol. Mandelate titers are for 1-ml scale cultures, prior to optimization and scale-up. Yields are given as mass of product divided by mass of substrate added (glycerol or phenylacrylic acid). The number of gene steps required to produce targets from primary metabolism, the number of enzyme orthologs screened, and the number o pathway constructs screened are presented (see [Tables S1--S2](#appsec1){ref-type="sec"}). Prior published titers in shake-flask are listed, along with the corresponding references.Table 1TargetCodeCASCompound classDays to production**Titer (mg/L)Titer (mM)Yield (g/g)**Genes requiredPathway figureEnzymes screenedPathways screenedPublished titer in shake-flask (mg/L)ReferenceCinnamic acidCIN140-10-3Phenylacrylic acids30669 ± 594.520.171[Fig. 3](#fig3){ref-type="fig"}A12650[@bib6]Coumaric acidCOU501-98-4Phenylacrylic acids30405 ± 642.470.091[Fig. 3](#fig3){ref-type="fig"}A12974[@bib35]Ferulic acidFER537-98-4Phenylacrylic acids--------3[Fig. S3A](#appsec1){ref-type="sec"}811196[@bib35]Urocanic acidURO3465-72-3Phenylacrylic acids40485 ± 993.510.121[Fig. 3](#fig3){ref-type="fig"}A55----StyreneSTY100-42-5Vinylbenzenes45318 ± 33.050.083[Fig. 3](#fig3){ref-type="fig"}A32 + 1836[@bib50]4-Vinylphenol4VP2628-17-3Vinylbenzenes4526 ± 70.220.013[Fig. 3](#fig3){ref-type="fig"}A32 + 1355[@bib34]4-Vinylguaiacol4VG7786-61-0Vinylbenzenes45[a](#tbl1fna){ref-type="table-fn"}504 ± 243.360.875[Fig. 3](#fig3){ref-type="fig"}A1011 + 164[@bib34]4-Vinylimidazole4VI3718-04-5Vinylbenzenes5417 ± 00.18\<0.013[Fig. 3](#fig3){ref-type="fig"}A75 + 1----CoumarolCMO20649-40-5Monolignols8125 ± 310.170.014[Fig. 4](#fig4){ref-type="fig"}A152 + 12[a](#tbl1fna){ref-type="table-fn"}854[@bib19]ConiferolCFO32811-40-8Monolignols81[a](#tbl1fna){ref-type="table-fn"}23 ± 20.130.046[Fig. S4A](#appsec1){ref-type="sec"}2211 + 12[a](#tbl1fna){ref-type="table-fn"}125[@bib19]ChavicolCHV501-92-8Allylbenzenes80[a](#tbl1fna){ref-type="table-fn"}28 ± 70.210.066[Fig. 4](#fig4){ref-type="fig"}A232 + 12+5----EugenolEUG97-53-0Allylbenzenes80[a](#tbl1fna){ref-type="table-fn"}102 ± 170.620.188[Fig. S4A](#appsec1){ref-type="sec"}3011 + 12+5[a](#tbl1fna){ref-type="table-fn"}25[@bib40]Muconic acidMUC1119-72-8Muconic acid8431 ± 160.220.015[Fig. S5A](#appsec1){ref-type="sec"}513153[@bib65]ButadieneBUT106-99-0Dienes--------7[Fig. S5A](#appsec1){ref-type="sec"}151 + 0----TyrosolTYO501-94-0Tyrosol--------4[Fig. S6A](#appsec1){ref-type="sec"}190†1316[@bib71](*S*)-Mandelic acidSMA17199-29-0Mandelates52170 ± 541.120.041[Fig. 5](#fig5){ref-type="fig"}A1213740[@bib61](*R*)-Mandelic acidRMA611-71-2Mandelates68251 ± 731.650.063[Fig. 5](#fig5){ref-type="fig"}A1715680[@bib61](*R/S*)-Mandelic acidXMA90-64-2Mandelates68220 ± 16/126 ± 251.45/0.830.092[Fig. 5](#fig5){ref-type="fig"}A1311----Phthalic acidPA88-99-3Benzenedicarboxylates--------5/7[Fig. S7](#appsec1){ref-type="sec"}20†----Isophthalic acidIPA121-91-5Benzenedicarboxylates--------5/7[Fig. S7](#appsec1){ref-type="sec"}20†----Terephthalic acidTPA100-21-0Benzenedicarboxylates--------5/7[Fig. S7](#appsec1){ref-type="sec"}20†145[@bib46]Isobutyric acidIBA79-31-2Isobutyl compounds--------2/3[Fig. S8C](#appsec1){ref-type="sec"}0[b](#tbl1fnb){ref-type="table-fn"}012,900[@bib70]IsobuteneIBE115-11-7Isobutyl compounds--------3[Fig. S8C](#appsec1){ref-type="sec"}0[b](#tbl1fnb){ref-type="table-fn"}0----2-Oxoisovaleric acidOIV759-05-7Chassis metabolites832.6 ± 0.7 (\>10xWT)§0.02--4[Fig. S8A](#appsec1){ref-type="sec"}318----PhenylalaninePHE63-91-2Chassis metabolites822352 ± 101 (4xWT)§12.98--4[Fig. S2A](#appsec1){ref-type="sec"}424200[@bib45]TyrosineTYR60-18-4Chassis metabolites821283 ± 230 (16xWT)§7.77\<0.014[Fig. S2A](#appsec1){ref-type="sec"}4102579[@bib39][^3][^4]

2. Results and discussion {#sec2}
=========================

2.1. Target selection {#sec2.1}
---------------------

The first step required selection of the chemical targets for the benchmark set. Selection from the chemical space of industrially relevant monomers was based on targets that are either found in natural biosynthesis routes, or are biosynthetically accessible based on literature information and prospective bio-retrosynthetic research. In total, we selected a list of 25 targets encompassing 7 compound classes that were either materials monomers or advanced precursors, including variants of current materials monomers ([Table 1](#tbl1){ref-type="table"}). This chemical diversity includes a broad range of compounds that are not native to the *E. coli* host ([Fig. 1](#fig1){ref-type="fig"}), and represents a number of challenges relevant to materials production: vinylbenzene targets were selected due to the chemical diversity accessible through biosynthetic routes and as less-energy intensive, sustainable alternatives to petrochemical equivalents; allylbenzenes form biodegradable polymers with novel routes to production and derivatization; mandelate lactides are used to prepare recyclable polymers, with chiral monomers accessible at high enantiomeric excess through enzymatic catalysis; butadiene is used to produce synthetic rubber, with biorefineries offering the potential to replace petrochemical cracking; isobutyl compounds are monomer targets accessible through clean biosynthesis routes; benzene dicarboxylates (phthalates) are high-volume material targets with prospects for regioselective biosynthesis; and tyrosol can be used for flame-retardant polymers, with fermentation offering simpler and less expensive purification than natural sources. Outside of the 7 primary compound classes, advanced precursor targets included the phenylacrylic acids (vinylbenzene intermediates), monolignols (allylbenzene intermediates) and muconic acid (butadiene intermediate). These targets offer compelling reasons for pursuing alternative synthetic biology solutions to production; however, ongoing assessment and reflection on the anticipated implications of the chosen targets for responsible innovation and sustainability is important.Fig. 1**Biosynthetic routes to material monomer targets**. Target compounds and primary metabolite precursors are represented as skeletal formulae, whilst other *E. coli* primary metabolites are shown as abbreviations. Continuous arrows show single enzyme conversion steps, and dashed arrows indicate multiple enzyme steps. Engineering of the *E. coli* host to boost production of primary metabolite precursors is highlighted in blue. Targets successfully produced *in vivo* are highlighted in green, with growth media titers indicated (asterisks show titers from feeding of phenylacrylic acid precursors). Orange targets were produced enzymatically *in vitro*. Where no active enzyme candidates were identified the targets are red, whilst enzyme steps to gray targets could not be verified within the benchmarking timeframe. Abbreviations used: 3-dehydroshikimate (3DS); 4-vinylguaiacol (4VG); 4-vinylimidazole (4VI); 4-vinylphenol (4VP); acetyl-coenzyme A (AcCoA); benzene dicarboxylate (BDC); benzene dimethanol (BDM); butadiene (BUT); coniferyl alcohol (CFO); chorismate (CHA); chavicol (CHV); cinnamic acid (CIN); coumaryl alcohol (CMO); coumaric acid (COU); 3-deoxy-D-arabinoheptulosonate-7-phosphate (DAHP); dihydroxyacetone phosphate (DHAP); 3-dehydroquinate (DHQ); erythrose-4-phosphate (E4P); 5-enolpyruvylshikimate-3-phosphate (EPSP); eugenol (EUG); fructose-1,6-bisphosphate (FBP); ferulic acid (FER); glucose-3-phosphate (G3P); glucose-6-phosphate (G6P); glucose (GLC); glycerol (GLY); glycerol-3-phosphate (GLY3P); histidine (HIS); 4-hydroxyphenylpyruvate (HPP); isobutyric acid (IBA); isobutene (IBE); muconic acid (MUC); 2-oxoisovaleric acid (OIV); phosphoenolpyruvate (PEP); phenylalanine (PHE); phenylpyruvate (PP); phosphoribosyl-pyrophosphate (PRPP); pyruvate (PYR); ribose-5-phosphate (R5P); (R)-mandelic acid (RMA); ribulose-5-phosphate (Ru5P); shikimate-3-phosphate (S3P); shikimate (SHK); (S)-mandelic acid (SMA); styrene (STY); tricarboxylic acid cycle (TCA); tyrosol (TYO); tyrosine (TYR); urocanic acid (URO); xylene (XYL). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

2.2. Design-Build-Test-Learn strategy {#sec2.2}
-------------------------------------

For each class of chemical target, synthetic metabolic pathways were selected following a semi-automated approach, which involved the use of retrosynthesis software tools such as RetroPath ([@bib25]), augmented with manual assessment of feasibility and identification of literature precedents. Enzyme candidates for each biosynthetic step were selected following a similar approach, using the computational tool Selenzyme ([@bib15]) and phylogenetic analysis, with final selection considering literature examples of expression and activity in *E. coli* where available. In most cases, where a single ideal enzyme candidate could not be identified, multiple orthologous enzymes were selected for activity screening. In total, 136 gene parts were designed and commercially synthesized (\~200 kilobase pairs of DNA; [Table S1](#appsec1){ref-type="sec"}), coding for enzymes in 25 putative biosynthetic pathways. The design phase, from target and pathway selection through to the design and ordering of DNA parts, took 10 days ([Fig. 2](#fig2){ref-type="fig"}). The turnaround time for gene synthesis was 30 days (with genes delivered in batches). Where multiple enzyme candidates were selected from different species to catalyze a given step, the enzymatic activity of these homologs was assessed using a 5-day automated enzyme screening pipeline. In total, 142 unique *in vitro* enzyme assays were performed (including both single and combinatorial cascade reactions), and through this process the best performing homologs ([Table S1](#appsec1){ref-type="sec"}) were earmarked for assembly into pathway constructs. Larger biosynthetic pathways were designed using a modular approach, with sub-pathways assigned to different vector backbones with compatible replication origins and antibiotic resistance markers. Pathways were split into modules that produced stable and quantifiable intermediates to aid troubleshooting, and allowed us to re-use certain modules where different targets shared common intermediates ([Fig. S1B](#appsec1){ref-type="sec"}). An optimal *design of experiments* approach was used to combine the selected genes for each pathway/module into a library of expression constructs, with genes arranged in different permutations and with regulatory elements of different strengths ([@bib14]). This approach allowed rapid prototyping of expression construct designs from screening a limited subset of potential combinatorial space, as well as providing robustness against assembly failures given the time constraints. Moreover, while it was not feasible to \'close the loop\' of the DBTL cycle within the strict 85-day time limit of this study, our statistical design of experiments was implemented in such a way that we not only identified well-producing prototype strains, but also were able to identify the underlying design rules that can be used to accelerate the next stage of optimization, as illustrated below for the example of mandelic acid production (section [2.9](#sec2.9){ref-type="sec"}).Fig. 2**Gantt chart representing key milestones and their dependencies within the biomanufacturing pipeline**. Steps within the DBTL pipeline are color-coded: Design (purple); Build (yellow); Test (gray); Learn (blue). Abbreviations within ovals represent target compounds and appear at their delivery points (3 letter codes are listed in [Table 1](#tbl1){ref-type="table"}). Targets successfully produced *in vivo* are green, red targets were not produced. Compound class abbreviations are: VBZ, vinylbenzene and phenylacrylic acid targets; ABZ, allylbenzene and monolignol targets; IBU, isobutyl compound targets; DIE, butadiene and muconate; MAN, mandelate targets; BDC, benzene dicarboxylate targets; TYO, tyrosol; and CHA, chassis metabolites. BDC targets are: terephthalic acid (TPA), isophthalic acid (IPA) and phthalic acid (PA). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 2

Once pathways and enzymes were selected, the construction and screening of target-producing strains followed a semi-automated DBTL pipeline described previously ([@bib14]), but with a number of additional optimizations. The combinatorial library of expression constructs was assembled through an automated approach using liquid handling robots following *in silico* generated worklists (*Supplementary Information - Build*). The resulting DNA constructs were screened first for the correct size by capillary electrophoresis, then subjected to next-generation sequencing to confirm correct assembly ([@bib23]). During the timeframe of this project our *first-pass* assembly efficiency (screening 4--6 clones per assembly) was 29%, with 115 of the 400 planned constructs successfully assembled ([Table S2](#appsec1){ref-type="sec"}). The sequence-verified expression constructs were then introduced into *E. coli* host strains for monitoring of chemical target production by mass spectrometry (MS; 11 bespoke methods established to quantify 40 target analytes; [Table S3](#appsec1){ref-type="sec"}). To further boost the titers of certain target compounds, 9 mutant bacterial strains were engineered to overproduce pathway precursors (tyrosine, phenylalanine and 2-oxoisovalerate; [Table S4](#appsec1){ref-type="sec"}) through a combination of targeted gene knockouts and overexpression of native genes including feedback-resistant mutations. In total, the whole process took 85 working days to perform in parallel for all the 25 material target projects ([Fig. 2](#fig2){ref-type="fig"}).

2.3. Chassis engineering for phenylalanine/tyrosine overproduction {#sec2.3}
------------------------------------------------------------------

A majority of the materials monomer targets are accessible through pathways that branch off from the native shikimate pathway for aromatic amino acid biosynthesis ([Fig. S2A](#appsec1){ref-type="sec"}). To enhance titers for these targets we undertook chassis engineering of *E. coli* strains (DH5α and MG1655) to boost production of phenylalanine and tyrosine ([@bib57]). First, we deleted the *tyrR* gene (a transcriptional regulator of aromatic amino acid biosynthesis) from the host cell genome, followed by deletion of either the *pheA* or *tyrA* genes (chorismate mutase/prephenate dehydratase (CMPDH) for phenylalanine and tyrosine biosynthesis, respectively). For pathways with aromatic aldehyde intermediates we also deleted the *feaB* gene (phenylacetaldehyde dehydrogenase). These knockout strains were then used as hosts for plasmids carrying a number of genes to channel carbon into the shikimate pathway. Transketolase (*tktA* gene) and phosphoenolpyruvate synthase (*ppsA*) both boost availability of shikimate pathway substrates, whereas 3-deoxy-D-arabinoheptulosonate 7-phosphate synthase (DAHPS; *aroF, aroG*) and CMPDH (*pheA, tyrA*) exist as amino acid specific isoforms that are feedback regulated. We incorporated mutations into our DAHPS and CMPDH genes to relieve feedback inhibition (denoted with a \* ([@bib38]; [@bib47]; [@bib51]; [@bib68])).

To boost tyrosine production, we designed a plasmid library containing the *tktA, ppsA, aroG\** and *tyrA\** genes. However, the *tktA* gene consistently failed to assemble into these constructs; therefore, we screened a panel of ten 3-gene plasmids without this gene ([Fig. S2B](#appsec1){ref-type="sec"}, [Table S2](#appsec1){ref-type="sec"}). In the Δ*tyrR,* Δ*pheLA* double knockout strain one plasmid clearly outperformed the rest (SBC005753), producing 1.28 g/L of tyrosine, representing a 16-fold improvement over the wildtype strain with no plasmid (0.08 g/L). To boost phenylalanine production, we designed a separate plasmid library containing *tktA, ppsA, aroF\** and *pheA\** genes, and noticed similar difficulties in assembling *tktA* into our constructs, however in this instance we identified two complete 4-gene plasmids (SBC008290 and SBC008376, [Table S2](#appsec1){ref-type="sec"}). The two plasmids were screened in the Δ*tyrR,* Δ*tyrA* double knockout strain ([Fig. S2C](#appsec1){ref-type="sec"}), producing 2.35 g/L and 1.96 g/L of phenylalanine respectively, representing a 3.9- and 3.2-fold improvement over the wildtype without plasmid (0.61 g/L). These engineered host strains, transformed with amino acid boost plasmids ([Fig. S2D](#appsec1){ref-type="sec"}), were used as described with target production plasmids to measure final target titers. For mandelic acid targets, later optimization work was done with double knockout strains in which the amino acid boost constructs were integrated into the genome, to relieve the burden on cells to maintain multiple plasmids in the presence of multiple antibiotics.

2.4. Production of phenylacrylic acid targets {#sec2.4}
---------------------------------------------

Phenylacrylic acids are intermediates along the pathways to our vinylbenzene and allylbenzene targets ([Fig. 3](#fig3){ref-type="fig"}A), but are also themselves interesting materials monomer targets. Cinnamic acid can be polymerized through its double bond to produce acrylic resins with high thermal stability ([@bib31]), or it can be co-polymerized with styrene or methyl acrylate ([@bib63]). In contrast, coumaric acid and ferulic acid can be polymerized through their carboxylate and hydroxyl moieties to form polyester materials that are cytocompatible for biomedical applications ([@bib64]). Given these potential materials uses of phenylacrylic acids, and since these compounds are intermediates towards several other monomer targets, we expressed the gene(s) for their biosynthesis from separate plasmid modules.Fig. 3(**A**) Pathways from amino acid substrates to corresponding *trans*-phenylacrylic acid and vinylbenzene/vinylimidazole targets. Enzyme abbreviations: PAL (phenylalanine ammonia-lyase); TAL (tyrosine ammonia-lyase); HAL (histidine ammonia-lyase); FDC (ferulic acid decarboxylase); and UbiX (flavin prenyltransferase). (**B**) Screening of ammonia-lyase candidates. Enzymes were expressed in DH5α cells with or without 3 mM amino acid feed. AtPAL (*Arabidopsis thaliana*) expressed from pBbA1a (SBC007575) and pBbA5a (SBC007580) plasmids. FjTAL (*Flavobacterium johnsoniae*) expressed from pBbA1a (SBC007583) and pBbA5a (SBC007589) plasmids. HAL candidates expressed from the pBbE2c plasmid, from which SBC007202 (BlHAL, *Burkholderia lata*) was selected. (**C**) Screening AnFDC (*Aspergillus niger*) activity with PaUbiX (*Pseudomonas aeruginosa*) and various substrates. Both enzymes were expressed from Ptrc promoters on a pCDF plasmid in DH5α cells with 3 mM substrate feed. (**D**) Best performing plasmid constructs. (**E**) *In vivo* production of targets. DH5α wildtype and double knockout (*ΔtyrR,ΔtyrA* (styrene) or *ΔtyrR,ΔpheLA* (vinylphenol)) strains transformed with indicated plasmids and assayed after 24 h.Fig. 3

Phenylalanine ammonia-lyase (AtPAL1, from *Arabidopsis thaliana*) and tyrosine ammonia-lyase (FjTAL, from *Flavobacterium johnsoniae*) were chosen on the basis of our prior work with these enzymes ([@bib14]), and were expressed from *trc* or *lacUV5* promoters ([Fig. 3](#fig3){ref-type="fig"}B). Both promoters yielded similar final titers of product, so we selected the P*trc* plasmids for both ammonia-lyase genes. The SBC007575 (AtPAL1) plasmid yielded 0.67 g/L (4.5 mM) of cinnamic acid when expressed in wildtype DH5α cells, or 1.2 g/L (8.1 mM) when media was supplemented with 3 mM phenylalanine; whereas SBC007575 (FjTAL) yielded 0.34 g/L (2.1 mM) coumaric acid, or 1.02 g/L (6.2 mM) when supplemented with 3 mM tyrosine. *E. coli* strains have been reported to produce 650 mg/L cinnamic acid ([@bib6]) and 974 mg/L coumaric acid ([@bib35]); however, these titers are for shake-flask cultures fed considerable quantities of glucose, so our 1-ml scale cultures compared favorably. For urocanic acid production, we selected 5 histidine ammonia-lyase (HAL) homologs for gene synthesis ([Table S1](#appsec1){ref-type="sec"}) and screened their activity in wildtype DH5α cells ([Fig. 3](#fig3){ref-type="fig"}B). All five HAL plasmids were functional, although SBC007202 (HAL from *Burkholderia lata*) was the most productive, yielding 0.48 g/L (3.5 mM) urocanic acid without media supplementation and 1.3 g/L (9.4 mM) with 3 mM histidine. We did not find prior literature reports for optimization of urocanic acid production in *E. coli*.

We attempted to construct a 3-gene pathway to ferulic acid using genes available in house ([Fig. S3A](#appsec1){ref-type="sec"}). This pathway progresses from tyrosine to L-DOPA (tyrosinase, TYR), then through caffeic acid (TAL from *Herpetosiphon aurantiacus*) to ferulic acid (caffeate *O*-methyl transferase, COMT). We designed a 12-member DoE library of ferulic acid plasmids and successfully constructed 11 ([Table S2](#appsec1){ref-type="sec"}). These plasmids were tested in wildtype DH5α cells and although they produced coumaric acid and L-DOPA, there was little detectable caffeic acid and no ferulic acid ([Fig. S3B](#appsec1){ref-type="sec"}). We subsequently tested the *in vitro* activity of our TYR and COMT enzymes, alongside a panel of homologs ([Fig. S3D](#appsec1){ref-type="sec"}; [Table S1](#appsec1){ref-type="sec"}), and found that our COMT (MsCOMT1, *Mentha spicata*) had poor activity with both L-DOPA and caffeic acid as substrates. Another issue with this pathway is likely to come from competition for tyrosine between TYR and TAL, generating coumaric acid which tyrosinase cannot process. In redesigning this pathway, we would seek to create a sequential route ([Fig. S3A](#appsec1){ref-type="sec"}), by replacing TYR with a coumarate 3-hydroxylase ([@bib8]) and expressing this alongside HaTAL and the best performing COMT enzyme (PkCOMT1, *Populus kitakamiensis*).

2.5. Production of vinylbenzene targets {#sec2.5}
---------------------------------------

Polystyrene is one of the most widely produced plastics, commonly used for protective packaging, food packaging and disposable cups/cutlery. It is produced by free-radical catalyzed polymerization of styrene through its vinyl moiety. 4-Vinylphenol (4VP) and 4-vinylguaiacol (4VG) are styrene derivatives that polymerize in a similar manner, provided the hydroxyl moieties are first protected ([@bib7]; [@bib62]). Poly(4-vinylphenol) is used in electronics applications due to its dielectric and photoresist properties, whilst poly(4-vinylguaiacol) is antimicrobial and potentially biodegradable ([@bib29]). 4-vinylimidazole (4VI) is another styrene analog that can form polymers with potentially novel properties, such as the absorbance of heavy metal ions ([@bib56]). Styrene and its derivatives are produced industrially from the unsustainable use of petrochemical feedstocks ([@bib17]). The decarboxylation of *trans*-phenylacrylic acids offers an alternative production process from a renewable resource, as these compounds are precursors in the biosynthesis of lignin by plants ([@bib9]).

We planned to produce vinylbenzene targets through a 2-step pathway ([Fig. 3](#fig3){ref-type="fig"}A). Amino acid substrates would first be converted to *trans*-phenylacrylic acids by ammonia-lyases, followed by decarboxylation by ferulic acid decarboxylase (FDC). FDC requires a prenylated flavin cofactor (PrFMN), and so to support enhanced production of this cofactor the enzyme UbiX was also included. We expressed the gene(s) for biosynthesis of phenylacrylic acids from separate plasmids (section [2.4](#sec2.4){ref-type="sec"}) to the FDC and UbiX genes. Replication origins and antibiotic resistance were selected to ensure compatibility of ammonia-lyase plasmids with amino acid overexpression plasmids, as well as with vinylbenzene and allylbenzene constructs ([Table S2](#appsec1){ref-type="sec"}). We were able to construct most of these plasmids immediately from genes already in house.

To produce the vinylbenzene targets, from *trans*-phenylacrylic acid precursors, we modified a plasmid carrying AnFDC (*Aspergillus niger*) and PaUbiX (*Pseudomonas aeruginosa*), kindly provided by a colleague (Prof. David Leys). We tested this plasmid (SBC007639) in wildtype DH5α cells grown in media supplemented with 3 mM of phenylacrylic acid precursors ([Fig. 3](#fig3){ref-type="fig"}C). We grew these cultures in gas-tight glass vessels and overlaid culture media with 50% v/v isooctane to capture the volatile products. With this set-up we successfully produced all four targets *in vivo*: 336 mg/L styrene; 71 mg/L 4VP; 504 mg/L 4VG; and 55 mg/L 4VI. Finally, to express full biosynthetic pathways we dual-transformed wildtype and double knockout strains of DH5α with ammonia-lyase and FDC plasmids ([Fig. 3](#fig3){ref-type="fig"}D). We measured our highest titer of styrene (318 mg/L) in the Δ*tyrR*, Δ*tyrA* strain and highest 4VP (26 mg/L) in the Δ*tyrR*, Δ*pheLA* strain ([Fig. 3](#fig3){ref-type="fig"}E). The highest literature titers for *E. coli* production of vinylbenzenes are from bioreactor cultures fed high quantities of glucose with gas-stripping of products; however, for shake-flask cultures, titers of 836 mg/L styrene, 355 mg/L 4VP and 64 mg/L 4VG have been reported ([@bib35]; [@bib50]). Titers for our prototype production strains compare favorably to the literature, especially since they were obtained at 1-ml scale with just 0.4% glycerol. Our highest titer of 4VI without urocanic acid feeding was 17 mg/L in wildtype DH5α ([Fig. 3](#fig3){ref-type="fig"}E). To our knowledge this is the first time 4VI has been produced in *E. coli*. With further time we would next combine ammonia-lyase genes with FDC and UbiX into full pathway constructs, these plasmids could then be co-transformed into our double knockout strains along with amino acid boost plasmids ([Fig. S2D](#appsec1){ref-type="sec"}). Vinylbenzenes are quite toxic to *E. coli* cells (styrene toxicity threshold is \~300 mg/L for *E. coli* ([@bib50])), so further improvements in production might require tolerance engineering or *in situ* product removal, for example by gas-stripping from bioreactor cultures.

2.6. Production of allylbenzene and monolignol targets {#sec2.6}
------------------------------------------------------

Lignin is a polymer component of plant cell walls, conferring mechanical strength to plant tissues and facilitating water-transport. Monolignols are the monomer precursors in lignin biosynthesis, and are crosslinked into a complex branched polymer structure ([@bib9]). The three common monolignols are coumaryl alcohol (coumarol), coniferyl alcohol (coniferol) and sinapyl alcohol; and there is significant interest in using these monomers to produce synthetic lignin mimics for materials applications ([@bib28]; [@bib52]). Monolignols are difficult to purify from plant materials, and so microbial production of these valuable compounds has been investigated ([@bib19]; [@bib32]). As well as their role in lignin biosynthesis, monolignols are also precursors in the biosynthesis of the allylbenzenes chavicol and eugenol, volatile compounds used as flavors and fragrances. Allylbenzenes resemble vinylbenzenes, with terminal double bonds for polymerization; however, most materials uses seek to polymerize through functionalization of the phenyl hydroxyl group, to preserve the allyl moiety for its antimicrobial properties ([@bib36]). For example, eugenyl methacrylate and ethoxyeugenyl methacrylate monomers are simple to prepare ([@bib58]), and have been polymerized into oil-absorbent microspheres ([@bib26]). Whilst chavicol-based benzoxazine monomers can been polymerized into thermoset resins with adjustable thermo-mechanical properties through controlled crosslinking ([@bib27]). Allylbenzenes have been produced from plant genes expressed in *E. coli*, but only from feeding of their respective monolignol precursors ([@bib40]). Therefore, we selected chavicol and eugenol, along with their precursors coumarol and coniferol, as targets for production.

Coumaric acid and ferulic acid can be produced in *E. coli* through pathways already described (section [2.4](#sec2.4){ref-type="sec"}). These *trans*-phenylacrylic acids can then be activated as CoA thioesters by 4-coumarate-CoA ligase (4CL), and reduced twice by cinnamoyl-CoA reductase (CCR) and cinnamyl-alcohol dehydrogenase (CAD) to yield coumarol or coniferol ([Figs. 4](#appsec1){ref-type="sec"}A and [S4A](#appsec1){ref-type="sec"}). Allylbenzenes can then be reached though acetylation by coniferyl alcohol acyltransferase (CFAT) and reduction by eugenol synthase (EGS). We selected 3--6 enzyme homologs for each step in this pathway ([Table S1](#appsec1){ref-type="sec"}) for *in vitro* enzyme screening ([Figs. 4](#appsec1){ref-type="sec"}B and [S4B](#appsec1){ref-type="sec"}). We could not identify functional 4CL and CCR candidates in a paired assay, presumably due to instability of the aldehyde products. For the remaining steps, PsCAD (*Pseudomonas sp.* strain HR199), PhCFAT (*Petunia hybrida*) and ObEGS (*Ocimum basilicum*) were the best performing candidates for both the chavicol and eugenol targets. A library of plasmid constructs was designed to express PsCAD with Gm4CL3 (Glycine max), which we knew to be functional from previous studies ([@bib14]), and all six CCR gene candidates. From this library we successfully constructed 12 plasmids ([Table S2](#appsec1){ref-type="sec"}), and screened *E. coli* DH5α transformants for monolignol production with feeding of phenylacrylic acid substrates ([Figs. 4](#appsec1){ref-type="sec"}C and [S4C](#appsec1){ref-type="sec"}). The best performing plasmid for coumarol (SBC009918) produced relatively little coniferol, and the best plasmid for coniferol (SBC009968) likewise produced little coumarol. These plasmids differ in the source of their genes for CCR (MtCCR1, *Medicago truncatula* for coumarol; PhCCR1 *P. hybrida* for coniferol), indicating that these enzymes discriminate between the two corresponding CoA thioesters ([Figs. 4](#appsec1){ref-type="sec"}A and [S4A](#appsec1){ref-type="sec"}). A second plasmid library was designed to express PhCFAT and ObEGS1, to convert monolignols into allylbenzene targets. We constructed 5 plasmid variants ([Table S2](#appsec1){ref-type="sec"}) and tested DH5α transformants for production of allylbenzene targets with monolignol feeding ([Figs. 4](#appsec1){ref-type="sec"}D and [S4D](#appsec1){ref-type="sec"}). For this library, a single plasmid (SBC009876) performed best at producing both chavicol and eugenol.

Combining the coumarol pathway plasmid ([Fig. 4](#fig4){ref-type="fig"}E; SBC009918) with the TAL plasmid ([Fig. 3](#fig3){ref-type="fig"}D; SBC007589) should allow for production of coumarol from tyrosine. The DH5α (Δ*tyrR* Δ*pheLA*) double knockout strain was transformed with the TAL plasmid alone, or in combination with the coumarol plasmid ([Fig. 4](#fig4){ref-type="fig"}F). In this strain, the TAL plasmid produced 405 mg/L of coumaric acid after 24 h culture in TBP media with 0.4% glycerol. This was a modest improvement over the 342 mg/L observed for this plasmid in wildtype DH5α cells ([Fig. 3](#fig3){ref-type="fig"}B). The double knockout strain with both the TAL and coumarol plasmids, produced 25 mg/L coumarol ([Fig. 4](#fig4){ref-type="fig"}F). To expand the pathway to chavicol, the double knockout strain was transformed with the coumarol and CFAT/EGS (SBC009876) plasmids, both together and singularly ([Fig. 4](#fig4){ref-type="fig"}G). The coumarol plasmid transformants yielded 97 mg/L of coumarol in media supplemented with 3 mM coumaric acid, however most of the coumaric acid substrate remained unconverted. Cells transformed with just the CFAT/EGS plasmid yielded 168 mg/L chavicol in media supplemented with 3 mM coumarol. In this case, whilst the substrate was not detectable after 24 h, chavicol titers were below the theoretical maximum of 403 mg/L (3 mM). It is possible that the substrate was converted to other side products by these cells, or alternatively the volatile chavicol product may have been lost from the media. When double knockout cells were transformed with both the coumarol and CFAT/EGS plasmids, 28 mg/L of chavicol was produced from the coumaric acid substrate ([Fig. 4](#fig4){ref-type="fig"}G).Fig. 4(**A**) Pathway from coumarate to coumarol and chavicol. Enzyme abbreviations: 4CL (4-coumarate-CoA ligase); CCR (cinnamoyl-CoA reductase); CAD (cinnamyl alcohol dehydrogenase); CFAT (coniferyl alcohol acyltransferase); and EGS (eugenol synthase). (**B**) Screening enzyme candidates in cell lysates with 3 mM substrate. No enzyme candidates were selected from the paired 4CL + CCR screen fed coumarate. PsCAD (*Pseudomonas* strain HR199) was selected to convert coumaraldehyde to coumarol. PhCFAT (*Petunia hybrida*) and OcEGS1 (*Ocimum basilicum*) were selected for converting coumarol to chavicol. (**C**) Screening coumarol pathway constructs in DH5α cells fed 3 mM coumarate. After 24 h, SBC009918 was the most productive plasmid. (**D**) Screening chavicol pathway constructs in DH5α cells fed 3 mM coumarol. After 24 h, SBC009876 was the most productive plasmid. (**E**) Best performing plasmid constructs. SBC007589 was screened in [Fig. 3](#fig3){ref-type="fig"}. MtCCR1 (CCR from *Medicago truncatula*), Gm4CL3 (4CL from *Glycine max*). (**F**) *In vivo* production of coumarate and coumarol. DH5α (*ΔtyrR ΔpheLA*) cultures with the indicated plasmids were assayed after 24 h. (**G**) *In vivo* production of coumarol and chavicol. DH5α (*ΔtyrR ΔpheLA*) cultures with the indicated plasmids were fed 3 mM coumarate or coumarol and assayed after 24 h.Fig. 4

Similar experiments were conducted for the coniferol/eugenol targets ([Fig. S4E](#appsec1){ref-type="sec"}); however, in this case no pathway to ferulic acid was available to connect to primary metabolism. Double knockout cells transformed with the coniferol plasmid ([Fig. S4F](#appsec1){ref-type="sec"}; SBC009968) yielded 23 mg/L coniferol from 3 mM ferulic acid substrate, whilst those transformed with the CFAT/EGS plasmid yielded 28 mg/L eugenol from 3 mM coniferol. Combining both plasmids in the double knockout strain gave our highest titer of 102 mg/L eugenol after 24 h culture, but with a significant amount of the ferulic acid substrate left unconverted ([Fig. S4E](#appsec1){ref-type="sec"}). To our knowledge this is the first time chavicol and eugenol have been produced microbially from phenylacrylic acid substrates. Coumarol and coniferol have been produced in engineered *E. coli* cells before, yielding 502 mg/L and 125 mg/L respectively in shake-flask cultures ([@bib19]). Given further time we would seek to consolidate the genes for coumarol/coniferol and chavicol/eugenol biosynthesis into single plasmid constructs, allowing production of these targets directly from tyrosine produced by the *E. coli* host. We would then further transform these cells with our tyrosine boost plasmid ([Fig. S2D](#appsec1){ref-type="sec"}; SBC005753) to channel carbon flux towards production of the targets. Similarities in structure between the allylbenzenes and styrene suggest that these targets may also be toxic and volatile, therefore further improvements in yield might be achieved through including an organic overlay or gas-stripping from bioreactor fermentations.

2.7. Additional material monomer targets {#sec2.7}
----------------------------------------

Butadiene is an important commodity chemical as a monomer for the production of synthetic rubber. The FDC enzyme has documented activity for converting sorbic acid into 1,3-pentadiene ([@bib2]), so we considered the potential for this enzyme to produce butadiene from muconic acid. For this purpose, we planned to construct a muconic acid pathway to support the potential *in vivo* production of butadiene. Muconic acid is also a materials target, which can be used as monomer for producing bio-based polyacrylate mimics ([@bib54]) and is a valuable platform chemical for the production of nylon, polyurethane and PET monomers. Muconic acid production by *E. coli* has been thoroughly explored, with a titer of 3.1 g/L reported for a 'metabolic funnel' pathway which converts the metabolites 3-dehydroshikimate (3DS) and chorismate into protocatechuic acid, then onto *cis,cis*-isomer of muconic acid ([@bib65]). Since it would be difficult to improve upon this highly optimized pathway ([Fig. S5A](#appsec1){ref-type="sec"}), we constructed a 5-gene plasmid encoding the same set of enzymes ([Fig. S5B](#appsec1){ref-type="sec"}). This pathway was tested in a range of wildtype and knockout host strains ([Fig. S5C](#appsec1){ref-type="sec"}), with a highest observed titer of 31 mg/L muconic acid (138 mg/L with 3DS substrate feeding). Although this was significantly less than the titer reported by Thompson et al., that study was conducted in shake-flasks with optimized media supplemented with 20 g/L glucose. We *in vitro* tested a panel a five different FDC homologs in combination with five UbiX homologs, for their ability to convert *cis,cis-* or *trans-,trans-*muconic acid into butadiene, but failed to detect this product. We also failed to observe butadiene production from muconic acid fed to *E. coli* cells carrying the functional FDC/UbiX plasmid (SBC007639), despite these cells producing 1,3-pentadiene from sorbic acid. Future projects to produce butadiene might consider screening a wider library of FDC homologs or undertaking mutagenesis of the active site to alter the substrate tolerance of this enzyme.

Tyrosol is an antioxidant compound found naturally in olive oil, that can be polymerized into flame-retardant plastics ([@bib10]). Tyrosol can be synthesized in *E. coli* by expressing phenylacetaldehyde synthase (PAAS) to convert tyrosine into 4-hydroxyphenylacetaldehyde (HPAA), which is then reduced by native aldehyde dehydrogenases (ADHs) into tyrosol ([@bib21]). Alternatively, tyrosine decarboxylase (TDC) can produce tyramine, which is acted upon by monoamine oxidase (MAO) enzyme to produce HPAA ([@bib59]). We aimed to improve on these studies by combining both routes in a 4-gene pathway ([Fig. S6A](#appsec1){ref-type="sec"}), including an exogenous ADH gene. We *in vitro* screened 6 enzyme homologs each for the PAAS, TDC and ADH enzymes, and 3 for MAO ([Fig. S6B](#appsec1){ref-type="sec"}; [Table S1](#appsec1){ref-type="sec"}). Whilst we discovered enzymes with good activity for all steps, the best performing homologs were those previously identified ([@bib21]; [@bib59]). For this reason, and due to time constraints, we did not continue work on tyrosol.

The benzene dicarboxylate terephthalic acid (TPA) is a monomer for polyethylene terephthalate (PET), the most widely produced plastic in the world, used to make clothing and food/drink containers. Isophthalic acid (IPA) and phthalic acid (PA) are isomers of TPA, and also commodity chemicals used to make plastics, often as copolymers with TPA. *E. coli* has been used for whole-cell biotransformation of *p*-xylene into TPA, using a 6-step (8 gene) pathway in a two-phase partitioning fermentation to achieve 96.7% conversion yield ([@bib46]). For this study we were interested in whether we could produce a shorter route to TPA, and whether we could produce IPA or PA from similar enzymes. A patented xylene monooxygenase (XMO, XylMA heterodimer) from *Sphingomonas* is reported to oxidize both methyl moieties of *p*- or *m*-xylenes in the production of hydroxymethyl benzoates ([@bib11]). We tested the ability of this enzyme, alongside the literature *Pseudomonas putida* XMO, to convert *o*-, *m*- or *p*-xylene into their respective methylbenzyl alcohol or benzenedimethanol products ([Fig. S7](#appsec1){ref-type="sec"}). However, using our *in vitro* enzyme assays we were unable to detect these products by MS from either XMO candidate. Given the lack of evidence for XMO functionality, we decided not to pursue the *in vivo* production of benzene dicarboxylates in favor of other targets.

2-oxoisovaleric acid (OIV) is an *E. coli* metabolite intermediate in the synthesis of valine, leucine and coenzyme A (CoA). Decarboxylation of OIV can be exploited for the synthesis of a variety of isobutyl compounds, including our targets isobutene and isobutyric acid. To boost OIV production we deleted the *ilvE* gene of DH5α, and designed plasmid constructs to overexpress four genes in the valine biosynthesis pathway ([Fig. S8A](#appsec1){ref-type="sec"}). We screened a library of these constructs in the *ΔilvE* strain and identified plasmid SBC008111 ([Fig. S8B](#appsec1){ref-type="sec"}) as the best performing construct, producing 2.61 mg/L of OIV. Although this was a modest level of production, OIV was undetectable in the wildtype strain without plasmid, and so this engineered chassis was selected to host pathways to isobutyl compound targets. Isobutene is a monomer for polyisobutylene (butyl rubber), widely-used for its gas-impermeability, whilst isobutyrate is an important precursor for the synthesis of the methyl methacrylate monomer of poly(methyl methacrylate) (PMMA, Perspex). We designed a biosynthetic pathway to isobutene following an established route to isobutanol (([@bib5]); [Fig. S8C](#appsec1){ref-type="sec"}). Decarboxylation of OIV by 2-keto acid decarboxylase (KDC) produces isobutyraldehyde which is then reduced by the native *E. coli* alcohol dehydrogenase (ADH). Isobutanol could then be converted into isobutene by oleate hydratase (OHD ([@bib49])). We selected 6 enzyme homologs for KDC and 9 for OHD ([Table S1](#appsec1){ref-type="sec"}) for *in vitro* enzyme screening. Isobutyric acid can also be produced in *E. coli* through the action of KDC followed by oxidation, provided several native aldehyde reductases are deleted ([@bib70]). We selected an alternative route through an acyl-CoA intermediate, using 2-oxoisovalerate dehydrogenase (ODH) and acyl-CoA ligase (ACL, [Fig. S8C](#appsec1){ref-type="sec"}). For this pathway we designed a plasmid library and successfully constructed 7 pathway variants ([Table S2](#appsec1){ref-type="sec"}) for screening in our engineered host. Methods for GC-MS detection of isobutene, isobutyric acid and various intermediates were developed, but the sensitivity of detection dropped significantly in culture medium, which meant these compounds could not be reliably quantified in enzyme and pathway screens. Therefore, further progress on these targets was not possible in the limited timeframe we had set ourselves.

2.8. Production of mandelic acid enantiomers {#sec2.8}
--------------------------------------------

Polymandelic acid (PMA) is a thermoplastic with polystyrene-like properties ([@bib44]), which can be thermally degraded for recycling. PMA can be prepared through ring-opening polymerization of mandelide (the cyclic dimer of mandelic acid (MA) ([@bib44])) or the *O*-carboxyanhydride derivative of MA ([@bib13]). Chemical synthesis of MA from petroleum-derived feedstocks is environmentally unsustainable, and requires further costly purification of (*R*)- and (*S*)-enantiomers. Therefore, bioproduction of enantiopure MA and derivatives from renewable feedstocks would further improve the green credentials of novel PMA materials. Biosynthetic pathways to MA enantiomers have been established in *E. coli* ([@bib61]). Oxidative decarboxylation of phenylpyruvate (PP) by hydroxymandelic acid synthase (HMAS) generates (*S*)-mandelic acid (SMA), which if desired can be oxidized by hydroxymandelate oxidase (HMO) then reduced by D-mandelate dehydrogenase (DMD) to yield (*R*)-mandelic acid (RMA; [Fig. 5](#fig5){ref-type="fig"}A). Engineered *E. coli* strains hosting these pathways produced 740 mg/L of SMA and 680 mg/L of RMA in shake-flask cultures, but PP accumulation suggests the HMAS step is a bottleneck ([@bib61]). For this reason, we focused on looking for alternative enzyme homologs with superior activities for the three biotransformation steps ([Fig. 5](#fig5){ref-type="fig"}B, [Table S1](#appsec1){ref-type="sec"}).Fig. 5(**A**) Pathways from phenylpyruvate to the (*S*)- and (*R*)-enantiomers of mandelate. Enzyme abbreviations: HMAS (hydroxymandelate synthase); HMO (hydroxymandelate oxidase); DMD (D-mandelate dehydrogenase); and MR (mandelate racemase). (**B**) Screening enzyme candidates. HMAS candidates expressed from the pBbE2c plasmid in DH10β cells fed 3 mM phenylpyruvate. SyHMAS (*Streptomyces yokosukanensis*) was the best performing enzyme. HMO and DMD candidates were screened in cell lysates fed 3 mM (*S*)-mandelate or phenylglyoxylate respectively. ScHMO (*Streptomyces coelicolor*) and RgDMD (*Rhodotorula graminis*) were selected as the best performing enzymes. (**C**) Screening (*R*)-mandelate pathway constructs in DH5α mutants (*ΔtyrR,ΔtyrA*). After 24 h, plasmid SBC009443 produced 251 mg/L (R)-mandelate with no detectable (S)-mandelate. (**D**) Screening (*R*/*S*)-mandelate pathway constructs in DH5α mutants (*ΔtyrR,ΔtyrA*). After 24 h, plasmid SBC009527 produced (*R*)- and (*S*)-mandelate at 220 and 126 mg/L, respectively (27% e.e.). (**E**) Final (*S*)-mandelate titre screen. SyHMAS was subcloned from pBbE2c (SBC007172) into pBbB5a (SBC010238) and screened in DH5α mutants (*ΔtyrR,ΔtyrA*) with or without the SBC008376 plasmid to boost phenylpyruvate production ([Fig. S2](#appsec1){ref-type="sec"}). (**F**) Best performing plasmid constructs. PpMR (MR from *Pseudomonas putida*).Fig. 5

We screened 12 different HMAS genes in our standard gene synthesis plasmid (pBbE2c) in *E. coli* and, although we saw uniformly low SMA titers even for the literature AoHMAS (*Amycolatopsis orientalis*), we identified SyHMAS (*Streptomyces yokosukanensis*) as the best performing homolog. We also conducted *in vitro* screening of three HMO and two DMD enzymes ([Fig. 5](#fig5){ref-type="fig"}B, [Table S1](#appsec1){ref-type="sec"}), but in this case the best performing enzymes ScHMO (*Streptomyces coelicolor*) and RgDMD (*Rhodotorula graminis*) were those from the literature ([@bib61]). The genes for the three best performing enzymes were used to design a library of RMA pathway plasmids, of which we constructed and sequence verified 15 ([Table S2](#appsec1){ref-type="sec"}). Screening of these plasmids in wildtype DH5α cells revealed a range of RMA titers from 22 to 251 mg/L, with generally no detectable SMA ([Fig. 5](#fig5){ref-type="fig"}C). However, it was notable that all plasmids also produced significant quantities of phenylglyoxylate (42--195 mg/L), the intermediate between SMA and RMA, perhaps due to the reversibility or product inhibition of the RgDMD enzyme. As an alternative route to RMA we designed a library of plasmids to express SyHMAS with PpMR (mandelate racemase from *Pseudomonas putida*). We successfully constructed 11 plasmids and screened them in wildtype DH5α ([Fig. 5](#fig5){ref-type="fig"}D; [Table S2](#appsec1){ref-type="sec"}), observing a fairly uniform ratio of 65% RMA to 35% SMA, with the most productive plasmid (SBC009527) yielding 220/126 mg/L RMA/SMA. Whilst this plasmid produced the most MA overall (346 mg/L in total), chiral resolution of these enantiomers would be necessary to yield a useful product, and again the presence of phenylglyoxylate highlights inefficiencies in the pathway.

The pathways to RMA pass first through SMA, suggesting that our SyHMAS enzyme is more productive when expressed from plasmids other than pBbE2c (ColE1 origin, *tet* promoter, *chl*^*R*^). We therefore subcloned SyHMAS into a different plasmid backbone, pBbB5a (BBR1 origin, *lacUV5* promoter, *amp*^*R*^). The original SyHMAS plasmid (SBC007172) was screened alongside the new plasmid (SBC010238) in a mutant DH5α strain (Δ*tyrR,* Δ*tyrA*), with or without co-transformation with a phenylalanine boost plasmid (SBC008376)([Fig. 5](#fig5){ref-type="fig"}E). There was a clear increase in SMA titer when comparing the original SyHMAS plasmid to the new plasmid (33 vs. 141 mg/L), and our highest SMA titer (170 mg/L) was achieved when the new plasmid was expressed in a host with enhanced carbon flux towards the PP substrate.

2.9. Optimization of mandelic acid production {#sec2.9}
---------------------------------------------

From our list of 25 material monomers and precursors we successfully constructed *E. coli* producer strains for 17 targets over an 85-day time limit ([Table 1](#tbl1){ref-type="table"}). This showcases the power of the biofoundry approach to rapidly prototype microbial production strains for materials monomer targets. Having developed these strains we anticipate that further significant improvements in target titers could be achieved through a focused optimization of the genetic construct design, further engineering of host strains, and fine-tuning of fermentation conditions for scale-up to bioreactor cultures. To explore this potential, we undertook a further time-limited project (65 days) to optimize and scale-up production of the (*S*)- and (*R*)-enantiomers of MA. We had already observed a significant increase in SMA titer when SyHMAS was subcloned from the pBbE2c vector into pBbB5a ([Fig. 5](#fig5){ref-type="fig"}E); this prompted us to investigate other expression vectors from the BglBrick collection (pBb vectors ([@bib42])). Design of experiments was used to select a library of 12 plasmids, sampling different combinations of replication origins (S = SC101, A = p15A, B = BBR1, E = ColE1), inducible promoters (1 = P*trc*, 2 = P*tet*, 5 = P*lacUV5*, 8 = P*bad*) and antibiotic resistance genes (a = *ampR*, k = *kanR*, c = *camR*). We successfully constructed 11 members of this library and screened them, along with our 2 original plasmids, in wildtype DH5α cultures ([Fig. 6](#fig6){ref-type="fig"}A). After 24 h, MA titers for these plasmids ranged from 8 to 100 mg/L, with the highest titer observed for pBbA1a-SyHMAS. This experimental data was used to model the effects of the different vector variables to predict MA titers for other vectors that were not tested. To validate the model, we constructed a second library of 6 plasmids, predicted to encompass high, medium and low MA producers. Screening of this second library showed good correlation between predicted and experimental titers (*R*^2^ = 0.88, *p*-value ≤ 0.006), and identified pBbB1a-SyHMAS (121 mg/L MA) as the optimal plasmid construct. In an attempt to further boost titers, we investigated the effects of gene dosage. We cloned one, two or three copies of SyHMAS (using different redundant codons to minimize sequence homology) into a single expression vector and cultured *E. coli* transformants to measure MA and HMA titers ([Figs. S9A and S9B](#appsec1){ref-type="sec"}). Whilst we observed no significant effect on MA production, HMA titers increased linearly for each additional copy of SyHMAS present (2.05-fold for two copies, 3.15-fold for three copies after 72 h).Fig. 6Optimization and scale-up of mandelic acid production. (**A**) Screening SyHMAS performance in different expression vectors. DoE was used to design a library of plasmids with different variables (replication origin, promoter and antibiotic resistance gene). This library (*blue*) was screened in DH5α cells along with two original plasmids (*red*; see [Fig. 5](#fig5){ref-type="fig"}). Analysis of mandelic acid titers after 24 h allowed modelling of predicted titers for different vector variables. A second library of 6 plasmids (*green*), predicted to include high, medium and low producers, was then constructed and screened. (**B**) Homology model of SyHMAS, showing the predicted position of hydroxymandelic acid (*yellow sticks*) and the catalytic Fe^2+^ ion. Residues targeted for mutagenesis are labelled in green. (**C**) Production of mandelic acid (*red*) and hydroxymandelic acid (*blue*) by selected SyHMAS mutants. Stacked bar heights represent the combined titer for each analyte, with the relative proportion of (*R*)- and (*S*)- enantiomers indicated (light and dark colors, respectively). (**D**) Mandelic acid titers for bioreactor cultures. Engineered *E. coli* strains hosting optimized mutant SyHMAS expression plasmids were cultured under conditions selected to favor production of the (*R*)- or (*S*)-enantiomers of mandelic acid (RMA & SMA) or hydroxymandelic acid (RHMA & SHMA). (**E**) Hydroxymandelic acid titers for bioreactor cultures described above. (**F**) Chiral analysis of mandelic acid (*red*) and hydroxymandelic acid (*blue*) produced by bioreactor cultures after 72 h. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 6

The native substrate for HMAS is hydroxyphenylpyruvate (HPP), which is converted to 4-hydroxymandelic acid (HMA). We anticipated that significant amounts of HMA will be produced as a side-product in our MA cultures, limiting productivity. However, HMA can be considered a material monomer target in its own right, which could be dimerized into hydroxymandelide for ring-opening polymerization. We developed new mass spectrometry methods, first to quantify both mandelic acid and hydroxymandelic acid in our cultures, then to determine relative proportions of (*R*)- and (*S*)-enantiomers for these targets. The specificity of HMAS for HPP over phenylpyruvate (PP) can be influenced by active site mutagenesis, as can the enantioselectivity of product formation ([@bib53]; [@bib55]). We undertook mutagenesis of our SyHMAS enzyme to determine whether we could replace our 3-step RMA pathway with a single enzyme, and to select mutants that favor production of MA over HMA. We prepared a homology model of SyHMAS in SWISS-MODEL ([@bib67]), using the crystal structure of AoHMAS bound to HMA ([@bib12]), and selected residues S204, I219 and I338 for mutagenesis ([Fig. 6](#fig6){ref-type="fig"}B). Each residue was randomized separately (by PCR using the NNK codon) and the library transformed into *E. coli* DH5α. Automated colony picking selected 96 colonies for each single mutation (3x coverage of NNK codon variants), and MA and HMA titers were quantified in 1-ml cultures after 24 h. Cultures with MA titers higher than wildtype HMAS were then selected for DNA sequencing and chiral analysis of the MA and HMA products ([Figs. 6C and S10](#appsec1){ref-type="sec"}). Chiral analysis for the wildtype enzyme showed that whilst the HMA produced was \>99.9% SHMA, the MA product contained \~7% RMA. The S204V mutation had the greatest effect on MA titers, enhancing these 3.1-fold to 206 mg/L. The S204V mutation also inverted the enantioselectivity of SyHMAS, yielding 92.9% RMA and \>99.9% RHMA, an effect that was more pronounced than described for other HMAS homologs ([@bib53]; [@bib55]). In contrast, the I219V mutation enhanced titers 2.2-fold over wildtype whilst retaining the selectivity for SMA & SHMA. The I338V mutation slightly improved the SMA/RMA ratio (96/4%), but reduced overall MA titer compared to I219V (106 mg/L vs. 145 mg/L). We subcloned the S204V and I219V mutants from the pBbB5a vector into both pBbE1a and pBbB1a, the best expression vectors identified from the library screen ([Fig. 6](#fig6){ref-type="fig"}A), and confirmed that pBbB1a supported the highest titers of MA and HMA ([Figs. S9C and S9D](#appsec1){ref-type="sec"}).

In parallel to optimization of our expression constructs, we sought to improve our host strain and identify optimal fermentation conditions for bioreactor scale-up. We already constructed gene knockout strains to support phenylalanine (Δ*tyrR*, Δ*tyrA*) and tyrosine (Δ*tyrR*, Δ*pheLA*) overproduction, along with ancillary plasmids to channel metabolic flux to these targets (SBC008290 and SBC005753 respectively). We further engineered these strains using recombineering with CRISPR editing to integrate the plasmid constructs into the genomes at the *lacZ* locus. This allowed us to use these engineered host strains (identified as DH5α(Phe+) and DH5α (Tyr+)) with just one plasmid (for SyHMAS) and antibiotic. To optimize fermentation conditions (temperature, stirrer speed, O~2~ feed-rate, etc.) we ran pilot fermenter cultures using our original pBbB5a-SyHMAS plasmid in wildtype DH5α cells. We also conducted 1-ml deepwell block cultures to screen different media compositions and carbon sources ([Fig. S11A](#appsec1){ref-type="sec"}). Once we had constructed our engineered host strains we further screened media requirements for constructs that produced predominantly (*S*)- and (*R*)-enantiomers of MA and HMA ([Figs. S11B and S11C](#appsec1){ref-type="sec"}). From these screens we identified our optimal strains and media for production of all four targets: SMA strain \[DH5α(Phe+) with pBbB1a-SyHMAS(I219V) in SOB-glycerol\]; RMA strain \[DH5α (Phe+) with pBbB1a-SyHMAS(S204V) in TBP-glycerol\]; SHMA strain \[DH5α (Tyr+) with pBbB1a-SyHMAS(I219V) in M9-glycerol\]; RHMA strain \[DH5α (Tyr+) with pBbB1a-SyHMAS(S204V) in M9-glucose\]. The four strains were grown in fermenter cultures in triplicate, with media samples taken at 24/48/72 h for quantification of MA ([Fig. 6](#fig6){ref-type="fig"}D), HMA ([Fig. 6](#fig6){ref-type="fig"}E) and chiral analysis ([Fig. 6](#fig6){ref-type="fig"}F). In addition, triplicate bioreactor cultures of the SMA and RMA strains were sampled after 72 h for genome and plasmid resequencing. No single-nucleotide variants were detectable above background noise, indicating that our producer strains were genetically stable over the duration of the fermentation. Our final scaled-up cultures yielded 0.97 ± 0.13 g/L MA (89% *S*-enantiomer), 0.80 ± 0.17 g/L MA (98% *R*-enantiomer), 4.78 ± 0.80 g/L HMA (\>94% *S*-enantiomer) and 0.90 ± 0.39 g/L HMA (99% *R*-enantiomer), respectively. Previously, titers of 1.02 g/L SMA and 0.88 g/L RMA were reported for *E. coli* shake-flask cultures ([@bib61]), whereas HMA was produced at 15.8 g/L in fed batch fermentation ([@bib43]) but with no indication of enantiopurity.

3. Conclusions {#sec3}
==============

We have demonstrated the rapid prototyping capabilities of an automated synthetic biology pipeline for the production of materials monomer targets. We successfully produced 17 chemically diverse key materials building blocks out of 25 selected targets, in some cases with titers close to those reported for optimized *E. coli* fermentations. This was achieved over an 85-day timeframe and without subsequent optimization. Overall, we estimate that the personnel and consumable costs amounted to approximately £15,000 (US\$18,500) per successful target compound, corresponding to an average of 360 personnel hours per compound. A second 65-day period was used for optimization and scale-up of strains capable of producing mandelic acid and hydroxymandelic acid. These strains produced 0.8--4.8 g/L of targets with high enantiopurity in fed-batch bioreactor cultures. This rigorous and comprehensive benchmarking study showcases the ability of biofoundries to provide quick access to a diverse range of materials monomers, and demonstrates how prototype microbial production strains can be rapidly scaled-up and optimized to achieve gram-scale fermentations. Through further iterations of the *Design-Build-Test-Learn* cycle, together with subsequent synthetic biology-based chassis engineering approaches for increasing fluxes, regulating enzyme expression and engineering enhanced enzyme performance; microbial production strains can be optimized to meet the technical specifications for industrial biomanufacturing. The rapid prototyping capacity demonstrated here establishes the foundation for a comprehensive biomanufacturing pipeline for the sustainable microbial production of diverse materials monomers.
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